463 related articles for article (PubMed ID: 8889726)
41. Intramuscular imipenem/cilastatin in multiple-dose treatment regimens: review of the worldwide clinical experience.
Garau J; Calandra GB
Chemotherapy; 1991; 37 Suppl 2():44-52. PubMed ID: 1879187
[TBL] [Abstract][Full Text] [Related]
42. Imipenem/cilastatin therapy for serious infections in neonates and infants.
Nalin DR; Jacobsen CA
Scand J Infect Dis Suppl; 1987; 52():46-55. PubMed ID: 3331042
[TBL] [Abstract][Full Text] [Related]
43. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.
McKinnon PS; Paladino JA; Grayson ML; Gibbons GW; Karchmer AW
Clin Infect Dis; 1997 Jan; 24(1):57-63. PubMed ID: 8994756
[TBL] [Abstract][Full Text] [Related]
44. Cost-analysis of imipenem-cilastatin monotherapy compared with clindamycin+aminoglycoside combination therapy for treatment of serious lower respiratory, intra-abdominal, gynecologic, and urinary tract infections.
Kreter B
Clin Ther; 1992; 14(1):110-21. PubMed ID: 1576620
[TBL] [Abstract][Full Text] [Related]
45. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections.
Niinikoski J; Havia T; Alhava E; Pääkkönen M; Miettinen P; Kivilaakso E; Haapiainen R; Matikainen M; Laitinen S
Surg Gynecol Obstet; 1993 Mar; 176(3):255-61. PubMed ID: 8382381
[TBL] [Abstract][Full Text] [Related]
46. Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections.
Solomkin JS; Wilson SE; Christou NV; Rotstein OD; Dellinger EP; Bennion RS; Pak R; Tack K
Ann Surg; 2001 Jan; 233(1):79-87. PubMed ID: 11141229
[TBL] [Abstract][Full Text] [Related]
47. Comparison of imipenem/cilastatin with the combination of aztreonam and clindamycin in the treatment of intra-abdominal infections.
de Groot HG; Hustinx PA; Lampe AS; Oosterwijk WM
J Antimicrob Chemother; 1993 Sep; 32(3):491-500. PubMed ID: 8262872
[TBL] [Abstract][Full Text] [Related]
48. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
Wiseman LR; Wagstaff AJ; Brogden RN; Bryson HM
Drugs; 1995 Jul; 50(1):73-101. PubMed ID: 7588092
[TBL] [Abstract][Full Text] [Related]
49. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections.
Brismar B; Malmborg AS; Tunevall G; Wretlind B; Bergman L; Mentzing LO; Nyström PO; Kihlström E; Bäckstrand B; Skau T
Antimicrob Agents Chemother; 1992 Dec; 36(12):2766-73. PubMed ID: 1336347
[TBL] [Abstract][Full Text] [Related]
50. [Study of imipenem-cilastatin at intensive care units].
Leroy J
Presse Med; 1990 Apr; 19(13):613-5. PubMed ID: 2139941
[TBL] [Abstract][Full Text] [Related]
51. Changing role of carbapenems in the treatment of lower respiratory tract infections.
Lode H; Hamacher J; Eller J; Schaberg T
Scand J Infect Dis Suppl; 1995; 96():17-23. PubMed ID: 7652498
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial.
Chen Z; Wu J; Zhang Y; Wei J; Leng X; Bi J; Li R; Yan L; Quan Z; Chen X; Yu Y; Wu Z; Liu D; Ma X; Maroko R; Cooper A
BMC Infect Dis; 2010 Jul; 10():217. PubMed ID: 20663130
[TBL] [Abstract][Full Text] [Related]
53. Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin.
Karadeniz C; Oğuz A; Canter B; Serdaroğlu A
Pediatr Hematol Oncol; 2000; 17(7):585-90. PubMed ID: 11033734
[TBL] [Abstract][Full Text] [Related]
54. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.
Fink MP; Snydman DR; Niederman MS; Leeper KV; Johnson RH; Heard SO; Wunderink RG; Caldwell JW; Schentag JJ; Siami GA
Antimicrob Agents Chemother; 1994 Mar; 38(3):547-57. PubMed ID: 8203853
[TBL] [Abstract][Full Text] [Related]
55. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
[TBL] [Abstract][Full Text] [Related]
56. [Multicenter comparative study of meropenem vs. imipenem in the intramuscular treatment of hospital infections of the urinary tract].
Tallarigo C; Comunale L; Baldassarre R; Poletti G
Minerva Urol Nefrol; 1995 Sep; 47(3):147-56. PubMed ID: 8815553
[TBL] [Abstract][Full Text] [Related]
57. A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections.
Angerås MH; Darle N; Hamnström K; Ekelund M; Engström L; Takala J; Viste A; Holme JB
Scand J Infect Dis; 1996; 28(5):513-8. PubMed ID: 8953684
[TBL] [Abstract][Full Text] [Related]
58. Intramuscular imipenem/cilastatin for treatment of mild and moderately severe bacterial infections.
Keller CA; Villavicencio J; Ramirez C
Scand J Infect Dis Suppl; 1987; 52():26-31. PubMed ID: 3483287
[TBL] [Abstract][Full Text] [Related]
59. Monobactams and carbapenems for treatment of intraabdominal infections.
Brismar B; Nord CE
Infection; 1999; 27(2):136-47. PubMed ID: 10219648
[TBL] [Abstract][Full Text] [Related]
60. Comparative clinical trial of imipenem-cilastatin (N-formimidoyl-thienamycin-dehydropeptidase inhibitor) and cefazolin.
Marier RL; McCloskey RV; Dickenson G; Sanders CV; Aldridge KE; Hoffman T; Gutterman D; Janney A
J Antimicrob Chemother; 1983 Dec; 12 Suppl D():133-9. PubMed ID: 6365873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
